Evaluation of lipoprotein(a) and adiponectin levels in patients with metabolic syndrome for the prediction of CVD risk

Introduction/Objective

Introduction: Metabolic syndrome (MetS) usually intensely forecasts cardiovascular diseases, along with elevating the risk of diabetes mellitus as well as chronic kidney disease. The International Federation for Diabetes (IDF) established in 2006 an accepted metabolic syndrome defined as a “cluster of the most dangerous heart attack and cardiovascular diseases risk factors”. Adiponectin is considered the most crucial factor which plays a serious role in glucose and lipid metabolism. Lipoprotein(a) Lp(a) was considered the single most common independent genetically inherited causal risk factor for cardiovascular diseases (CVD). bolic syndrome patients.

Methods/Case Report

Objectives: To investigate the correlation between Lipoprotein (a) and adiponectin in metabolic syndrome patients with CVD.

Subjects and methods

This research was performed at Al-Ahliyya Amman University (AAU) during the period between January 2021 and March 2021. Eighty participants were randomly selected from patients who were recruited from the internal medicine clinics. The participants aged 40 to 60 years were selected after screening for the criteria for diagnosis with MetS. Forty-two of the participants had metabolic syndrome, while the other 38 represented the control group. Adiponectin and Lipoprotein (a) were measured using by ELISA technique. Routine laboratory tests, including a lipid profile, glucose and body mass index (BMI), were measured for all participants.

Results (if a Case Study enter NA)

Results: Plasma lipoprotein (a), HDL, and LDL levels were significantly higher in MetS patients than in healthy controls p= 0.026, 0.04, and 0.04, respectively. In comparison, no significance was found regarding adiponectin (p = 0.07).

Lipoprotein (a) had shown a negative correlation with HDL(r= -0.34), whereas adiponectin was inversely correlated with LDL (r= -0.33) and LDL/HDL ratio (r= -0.34). The multiple linear regression analysis results revealed the predictive potential of Lipoprotein (a), and adiponectin when used in different models for CVD risks using HDL as a risk factor (r = 0.381, p = 0.047).

Conclusion

The studied metabolic syndrome markers might be essential in detecting cardiovascular events. It can be concluded that Lipoprotein (a) and adiponectin can be used to predict the CVD risks in meta